Find an expert

Junxian Lim is an accomplished molecular biologist at the Institute for Molecular Bioscience. With a strong background in cell biology, protein biochemistry, and pharmacology, he has established himself in the field. Collaborating with researchers at universities, institutions, as well as international industry partners like AstraZeneca and Sosei Heptares, he has contributed significantly to advancing scientific knowledge.

Throughout his doctoral studies, Junxian authored seven ground-breaking studies focused on the development of novel bioactive inhibitors targeting immune cells and inflammatory diseases. These contributions have paved the way for innovative approaches to drug development. Utilizing his expertise, he has successfully developed and characterized a diverse range of protein and cellular assays that enable in-depth investigations into immunity and inflammation. His research findings have been published in prestigious scientific journals, including Nature Communications, Cell Reports, Journal of the American Chemical Society, Diabetes, Journal of Medicinal Chemistry, and the British Journal of Pharmacology. His work has been highly cited, reflecting its impact and significance within the scientific community.

Recognized for his outstanding mentoring abilities, Junxian has supervised or co-supervised the research of two completed PhD students, six completed MPhil students, and three completed Honours students. The success of his former students is a testament to his dedication and guidance. They continue to excel and actively contribute to research endeavours around the world, spanning countries such as Australia, Singapore, Korea, India, Japan, and China.

Beyond his research and mentoring achievements, Junxian actively participates in the scientific community. He serves on the editorial boards of esteemed journals like Journal of Translational Medicine, Frontiers in Molecular Biosciences and Biology. This involvement allows him to stay at the forefront of scientific advancements and contribute to the dissemination of knowledge within his field.

Over 5 years of experience in translational biomedical research, specialising in monoclonal antibody-based therapies, immuno-oncology, target discovery and theranostics in cancer. My main research focus is on targeted cancer therapies, understanding how target receptor endocytosis affects antibody drug conjugate (ADC) and radioligand therapy delivery, immune-mediated ADCC, and how combination therapies with immune checkpoint inhibitors can potentially improve therapeutic outcomes for patients.

Neurologist

Dr McCombe graduated in Medicine from UQ and completed a Science degree for medical students. She then trained as a neurologist in Sydney, at Prince Henry and Prince of Wales Hospitals. She obtained a PhD from the University of Sydney. She obtained experience in Neurophysiology in Cleveland and then returned to UQ as a post-doctoral fellow. She worked for some years as a research fellow in Neuroimmunology and was an NHMRc SRF. Later she resumed clinical practice as a neurologist, and contimued her research as an NHMRC Practitioner Fellow. She is currentlyProfessor and Head of the Royal Brisbane Clinical school in the School of Medicine and Co-head of the Brain and Mental Health Theme at the UQ Centre for Clinical Research.

Dr Moniruzzaman is working as a Senior Postdoctoral Research Fellow at the UQ Faculty of Medicine and PA Hospital of Metro South Health. His research focuses on the molecular pathobiology of inflammatory diseases, in particular, how mucosal epithelial cells and gut microbiota regulate immune function in the gastrointestinal (GI) tract and contribute to different diseases, including inflammatory bowel diseases (IBD) and functional GI symptoms called disorders of gut-brain interactions (DGBI). Dr Moniruzzaman received his PhD from The University of Queensland in 2020, where he studied how the interleukin(IL)-20 family of cytokines (IL-20, IL-22, and IL-24) regulate mucosal epithelial and immune function in inflammatory and infectious diseases, including ulcerative colitis (UC) and respiratory syncytial virus. After graduation, he received postdoctoral training in the IBD Lab at Mater Research Institute – UQ and Nanomedicine Lab at UQ School of Pharmacy, where he investigated the role of cannabinoid receptors in UC and colitis-associated colorectal cancer, development of cannabinoid formulations to treat UC, and involvement of autophagy gene Atg7 in 6-Thioguanin mediated protection from UC. He was awarded a highly competitive UQ Postdoctoral Research Fellowship (2021-2022) and UQ School of Pharmacy Strategic Grant (2022) to study cannabinoids and Atg7 in UC, Translational Research Institute LINC Grant (2023) to study cannabinoids in palliative care of patients with advanced cancer, and Metro South Health SERTA (2024-2025) to study non-antibiotic treatment of SI dysbiosis in patients with DGBI. His current work focuses on how small intestinal dysbiosis controls the mucosal immune microenvironment and contributes to the pathogenesis of DGBI, including irritable bowel syndrome (IBS), functional dyspepsia (FD), and gastroparesis.

Dr Moyle’s laboratory (www.moylelab.com) uses cutting edge technologies for the synthesis of peptides, protein expression, and protein semi-synthesis to gain insights into the functional roles played by various biochemical pathways, to engineer better protein and peptide therapeutics, and to improve the delivery characteristics of various therapeutic molecules. Specific current areas of interest are detailed below:

1. Subunit Vaccine Development: methods to develop improved vaccines through the combination of recombinant and synthetic approaches to improve immunopotency and tailor immune responses (links to reseach articles on semisynthetic vaccines and peptide vaccines; reviews on vaccine development).
2. Delivery Systems for Nucleic Acid-Based Molecules: multi-component synthetic and recombinant approaches to improve the cellular uptake, and targeted delivery of various oligonucleotide molecules (e.g. siRNA, mRNA, pDNA and CRISPR-Cas9) as an exciting approach to treat or prevent various diseases (links to research articles and reviews).
3. Deciphering the Roles of Post-Translational Modifications: The combination of peptide synthesis and protein semisynthesis to enable the production of large amounts of site-specifically modified species, that can be used to deconvolute the roles played by various post-translational modifications (links to research articles).
4. Peptide/Protein Drugs and Delivery: The study of methods to improve the delivery characteristics of peptide/protein drugs (e.g. poor oral absorption, instability to chemical/enzymatic degradation, and the inability to reach their site/s of action) through chemical engineering approaches.
5. New Approaches for Superbugs: the development of antivirulence approaches, and formulations (e.g. various types of nanoparticles - silver, protein, mesoporous silica), which reduce the ability for microbes to cause disease, and make them more readily treated with antimicrobials, by providing access to synergistic combinations, and reducing the risk of antimicrobial resistance.

Information for Potential Students:

The Moyle lab considers applications from potential students and postdoctoral fellows with an interest in: i) infection control (including subunit vaccine and antimicrobial development); ii) delivery systems for peptide therapeutics; iii) targeted delivery systems; iv) studying the function of posttranslational modifications; and v) delivery systems for nucleic acid-based therapeutics (e.g. siRNA, shRNA, miRNA, mRNA, pDNA and CRISPR-Cas9). If you are interested in working in any of these areas please feel free to contact Dr Moyle (p.moyle@uq.edu.au). Please ensure that you supply an up to date CV; describe why you would like to work in the Moyle lab; provide a listing of publications (preferably with impact factors and citation counts); and indicate what skills you would bring to the lab. Detailed information on our laboratory is available at www.moylelab.com. Preference will be given to students and postdoctoral fellows who have their own funding.

Dr Moyle Biosketch:

Dr Moyle (H-index 30, >2600 citations; >95 publications; 13/8/2024; Google Scholar, ORCID, ResearcherID, and Publons profiles) received a PhD (Dec 2006) and a Bachelor of Pharmacy (Hons I) (Dec 2001) from The University of Queensland (UQ); graduated from the Pharmaceutical Society of Australia pre-registration pharmacist-training course (Nov 2002); and is registered with the Pharmacy Board of Australia. He currently works as an Associate Professor in the UQ School of Pharmacy, where he has been based since 2014.

Dr Moyle works in the fields of medicinal chemistry, chemical biology, and drug formulation, investigating subunit vaccine development, outcomes associated with histone post-translational modifications, and methods to improve the delivery characteristics of oligonucleotide (e.g. siRNA and pDNA), peptide, and protein therapeutics. During his PhD, Dr Moyle developed methods that enabled the synthesis of pure, lipid adjuvanted peptide vaccines, using advanced chemical ligation techniques. In addition, the conjugation of mannose to combined prophylactic/therapeutic human papillomavirus type-16 vaccines, to target dendritic cells, was demonstrated to significantly improve vaccine anti-tumour activity. This work, conducted with leading researchers at the QIMR Berghofer Medical Research Institute (Prof Michael Good & Dr Colleen Olive), established Dr Moyle’s national and international profile in the field of vaccine development, resulting in 11 peer reviewed papers, including top journals in the field (J Med Chem; J Org Chem), as well as 6 review articles and 2 invited book chapters.

Dr Moyle undertook his postdoctoral training in the laboratory of one of the world’s premier chemical biologists, Professor Tom Muir (the Rockefeller University, NY, USA; now at Princeton University, NJ, USA). During this time he developed an extensive knowledge of techniques for protein expression, bioconjugation, bioassays, and proteomics, which represent an essential skill set required for this proposal. As part of this work, Dr Moyle developed novel synthetic routes to generate site-specific ADP-ribose conjugated peptides and proteins. This research was hailed as a major breakthrough in the field, leading to several collaborations, and an exemplary publication in the prestigious chemistry journal JACS. This vast body of work identified the enzyme (PARP10) responsible for mono-ADP-ribosylation of histone H2B, and demonstrated interactions between this modification and several proteins, including BAL, which is associated with B cell lymphomas. In addition, a number of robust chemical methods were developed to enable the synthesis of a complete library of methyl-arginine containing histones, which were incorporated into synthetic chemically-defined chromatin to investigate the site-specific effects of arginine methylation on histone acetylation. This work led to a collaboration with colleagues at Rockefeller to investigate the effects of histone arginine methylation on transcription.

Teaching:

Dr Moyle teaches into the following subjects in the UQ School of Pharmacy.

• PHRM3011 (Quality Use of Medicines) - course coordinator
• PHRM4021 (Integrated Pharmaceutical Development)
• PHRM3021 (Dosage Form Design)
• PHRM2040 (Drug Discovery)

Awards:

2016 - Health and Behavioural Sciences (HABS) faculty commendation for Early Career Citations for Outstanding Contributions to Student Learning (ECCOSL)

2015 - ChemMedChem top 10 cited article of 2013 (link)

2014 - Highest ranked NHMRC development grant (2013; APP1074899)

2013 - Institute for Molecular Biology (IMB) Division of Chemistry and Structural Biology Prize

Dr Natacha Omer is a paediatic oncologist at the Queensland Children's Hospital in Brisbane. She is specialised in solid tumours, with a spacial interest in paediatric and adolescent sarcomas, cancer immunotherapy and molecular oncology. She is undertaking a PhD in immunology studying natural killer (NK) cell immunotherapy in paediatric sarcomas at the Frazer Institute, University of Queensland, in Dr Fernando Guimaraes lab.

Dr Osborne, BSc(Hons), MAgSc, PhD is an epidemiologist and toxicologist with research interests in using environmental epidemiology to examine aetiology and pathological pathways of disease. He has worked on a range of projects examining environmental exposures and health outcomes including exposure to metals, pollen, mould, chronic exposures to low levels of chemicals, pesticide and cyanotoxins. He also has experience examining how exposure to the environment may increase health and wellbeing (green/bluespace and solar irradiance and vitamin D).

He has developed skills in the linkage of environmental and population health data in an interdisciplinary context, and has expertise in design, linkage, hypothesis formulation, analysis, interpretation, translation and dissemination.

He has experience in designing and collecting epidemiological data and initiating studies of primary collected data (HealthIron, HealthNuts, Cornwall Housing Study, Survey of Recreational Water Users, Monitoring of Meniere’s Symptoms).

He also has used secondary data from existing cohorts (NHANES, UK Biobank, 1958 Birth Cohort, British Household Survey, Melbourne Collaborative Cohort Study, South Asian Clinical Toxicology Research Collaboration), as well as linkage of previously unconnected “big data” sets in mashups on novel platforms (MEDMI project). He has used traditional statistical methods such as linear/logistic regression, time series analysis, interrupted time series and Cox regression to ascertain associations between exposures and outcomes, as well as integrating confirmatory structured equation modelling with environmental/health data sets to construct conceptual diagrams of associations and assess pathway directions.

He currently researches pollen and health outcomes as well as chronic kidney disease in low to middle income countries.

He has supervised 6 PhD students to completion (2 primary supervisor, 4 co-supervisor) and currently supervises 4 PhD student. He has been associate editor of Archives of Environmental and Occupational Health since 2011 and is on the editorial board of International Journal of Epidemiology and Pediatric Allergy, Immunology and Pulmonology. He is a member of Australasian Epidemiology Association, International Society of Environmental Epidemiology and International Epidemiology Association.

He has previously worked at the Universities of NSW, Sydney, Exeter, Melbourne, Portsmouth, Queensland and Flinders, the Murdoch Children’s Research Institute and the Cancer Council Victoria. He completed his PhD at the School of Population Health, University of Queensland/National Research Centre of Environmental Toxicology working on the toxicology and public health effects of cyanobacterial toxins in southeast Queensland.

Prof Ben Panizza is the Chairman of Otolaryngology - Head and Neck Surgery for Metro South and Director of the Queensland Head and Neck Cancer Centre. He has been active in head and neck cancer management for 25 years. He has created innovative approaches in dealing with malignancies extending to the skull base one of the most anatomically complex regions of the body. He is recognised as a world leader in cutaneous malignancy extending to the temporal bone and perineurial spread of keratinocyte skin cancers, being regularly invited overseas to present. Prof Panizza is active in integrating new treatments with surgery to change treatment paradigms and improve outcomes for patients. He is a professor in the Faculty of Medicine at the University of Queensland and works collaboratively with basic scientist and has supervised to completion 25 research higher degrees over the last 10 years. He has established an in department clinical trials unit to run clinical trials from proof of principle to phase 3 clinical trials enabling access and rapid translation for his scientific partners at the Princess Alexandra Hospital which has one of Australia's largest head and neck clinics. Prof Panizza is a clinical consultant and advisor to industry (Merck, Sanofi, QBiotics, Decibel Therapeutics) and sits on the governing bodies of both the International Federation of Head and Neck Oncological Societies and The World Federation of Skull Base Societies. He is active in publishing and sits on the editorial boards of the major head and neck journals (Head Neck, Oral Oncology, Skull Base, ANZ Journal of Surgery).

Emeritus Professor Michael Pender graduated from The University of Queensland in 1974 with First Class Honours in Medicine and a University Medal. Over the next six years he trained as a physician and neurologist at the Royal Prince Alfred Hospital and St Vincent's Hospital, Sydney, and became a Fellow of the Royal Australasian College of Physicians (FRACP) in 1981. During his specialist clinical training he developed a keen interest in multiple sclerosis which he has continued since then. After completing his clinical training in neurology, he was a research scholar in the field of multiple sclerosis at the Institute of Neurology, Queen Square, London, and was awarded a PhD from the University of London and Queen Square Prize for Research in 1983. From 1984 to 1986 he continued this research as a Research Fellow at the John Curtin School of Medical Research, Australian National University, Canberra. In 1987 he was appointed Senior Lecturer in the Department of Medicine, The University of Queensland, at the Royal Brisbane Hospital. In 1989 he was awarded a Doctorate of Medicine from The University of Queensland for his research in the field of multiple sclerosis and was promoted to Reader in Medicine. In 1995 he was promoted to Professor of Medicine (Personal Chair), The University of Queensland, which he held until his retirement in 2021. His main clinical and research interest is multiple sclerosis. He also held the positions of: Consultant Neurologist, Royal Brisbane and Women's Hospital, 1987–2021; Director of Neurology, Royal Brisbane and Women's Hospital, 1992–2005: Director of the Neuroimmunology Research Centre, The University of Queensland, 1991–2007; Director of the Multiple Sclerosis Research Centre, The University of Queensland, 2009–2014; and Clinical Fellow, QIMR Berghofer Medical Research Institute, 2017–2021. In 1996, with the support of the Multiple Sclerosis Society of Queensland, he established a Multiple Sclerosis Clinic at the Royal Brisbane and Women's Hospital. In 2006 he was awarded the Multiple Sclerosis Australia Prize for Multiple Sclerosis Research - "For outstanding commitment and dedication to research into the cause and cure of Multiple Sclerosis in Australia". In 2011 he received the John H Tyrer Prize in Internal Medicine, The University of Queensland, for research in the field of Internal Medicine. He was the Sir Raphael Cilento Orator of the Royal Australasian College of Medical Administrators for 2009 and the W Ian McDonald Lecturer of the Australian and New Zealand Association of Neurologists for 2014. In 2019 he received the John Studdy Award from Multiple Sclerosis Australia for "lifelong commitment and service to research to identify the cause of and potential cure for Multiple Sclerosis". In 2024 he was appointed a Member of the Order of Australia for significant service to medicine, particularly neurology and multiple sclerosis research, and to tertiary education. Major research achievements include: the discovery of apoptosis of autoreactive T cells in the central nervous system as a fundamental mechanism of recovery from autoimmune attack (Journal of the Neurological Sciences 1991, Journal of Autoimmunity 1992, European Journal of Immunology 1994); formulation of a novel hypothesis (The Lancet 1998) proposing a failure of this mechanism in multiple sclerosis; and the further development of this hypothesis into a new paradigm (Trends in Immunology 2003) for the cause of human chronic autoimmune diseases based on infection of autoreactive B cells with the Epstein–Barr virus (EBV), some of the predictions of which have already been verified in multiple sclerosis, rheumatoid arthritis and Sjögren’s syndrome. His EBV hypothesis led to the first clinical trial of EBV-specific T cell therapy in multiple sclerosis (JCI Insight 2018), a trial in which he was a principal investigator.

Group page: https://medicine-program.uq.edu.au/multiple-sclerosis-research-group

Dr. Ove A. Peters joined the University of Queensland, Brisbane, Australia, in 2020 after faculty positions in Heidelberg, Germany and Zurich, Switzerland, as well as at the University of California, San Francisco. Most recently, he was the founding director of the postgraduate endodontic program at the Arthur A. Dugoni School of Dentistry in San Francisco, a professor with tenure and the Chair of the Department of Endodontics at that school.

Dr. Peters has wide-ranging clinical and research expertise and has published more than 200 manuscripts related to endodontic technology and biology. He has authored two books and contributed to several leading textbooks in dentistry; he also is an associate editor for the International Endodontic Journal as well as the Australian Endodontic Journal, an academic editor for PLOS One and serves on the review panel of multiple other journals. Among others awards, Dr Peters has received the Hans Genet Award of the European Society of Endodontology and more recently the Louis I. Grossman Award of the American Association of Endodontists. He is a Diplomate of the ABE, a member of OKU and a Fellow of the International and American Colleges of Dentistry.

Dr. Divya Ramnath is a post-doctoral researcher in Prof. Matt Sweet's lab at the Institute for Molecular Bioscience (IMB), The University of Queensland. As an early career post-doctoral researcher, she led a new project, characterising inflammation-associated determinants of chronic liver disease at the IMB Centre for Inflammation and Disease Research (CIDR).

I am a Principal Investigator (PI) and a senior research officer (SRO) at Mater research – UQ with excellent clinical and research laboratory skills and expertise in conducting and analyzing laboratory assays and resolving complex research and clinical laboratory problems. I can describe myself as determined, reliable, studious, conscientious, attentive, industrious, diligent, and focused on the timely, quality completion of all lab procedures. I am able to work well under pressure and time constraints within high-volume environments both independently and in collaboration within a team. I am also a highly self-motivated and career-oriented individual with a genuine interest in addressing cancer molecular mechanisms with the goal of developing novel cancer therapeutics and immunotherapy focusing on tumor microenvironment, immunoregulation and signaling pathways in cancer and metastasis.

A/Prof Barbara Rolfe is a Group Leader at the Australian Institute for Bioengineering and Nanotechnology. A/Prof Rolfe is an immunologist and cell biologist, whose major research interests are the role of the innate immune system in cancer, the identification of novel therapeutic strategies for cancer, and nanomaterial safety. Her research has led to the identification of a previously unknown mechanism by which dysregulation of the immune system contributes to cancer development and growth, and provided information regarding the immune response to nanomaterials and the influence of physicochemical characteristics on biodistribution and cellular uptake. A/Prof Rolfe has used mouse models and small peptide agonists and antagonists to investigate the role of the innate immune system in tumour development and growth. This research demonstrated for the first time an important role for complement proteins in promoting tumour growth via regulation of immunosuppressive innate immune cells. Ongoing research is aimed focussed on gaining a better understanding of the role of complement proteins in tumour growth, developing novel immunotherapeutic strategies for cancer and investigating the application of nanomaterials for targeted delivery of anti-cancer drugs.

Prof Katharina Ronacher obtained an MSc degree in Medical Biochemistry from the University of Vienna (Austria). Thereafter, she was awarded a prestigious fellowship from the Austrian Ministry of Science and Technology to complete a PhD at the University of Cape Town (South Africa). She completed her post-doctoral fellowship at Stellenbosch University, where she was subsequently offered a faculty position. Prof Ronacher was Senior Scientist on several large clinical research trials funded by the Bill and Melinda Gates Foundation, the European Union and the US National Institutes of Health with focus on identification of biomarkers for tuberculosis (TB) treatment response. In parallel, she established her independent research group investigating how endocrine factors impact immune responses to TB, for which she received uninterrupted funding from national and international funding bodies since 2008. In 2015, she was awarded a NIH R01 grant for her ground-breaking research into the underlying immunological and metabolic mechanisms of increased susceptibility of diabetes patients to TB. With this grant she has lead the international ALERT Consortium with clinical field sites in South Africa and at the Texas/Mexico border.

She relocated to Brisbane in 2017, where she now heads the Infection, Immunity and Metabolism group at the Mater Research Institute – University of Queensland, but continues to collaborate with clinicians and researchers in South Africa, the USA and Europe and holds an affiliate appointment as Professor Extraordinary at Stellenbosch University.

Prof Ronacher's current research investigates the underlying immunological mechanisms contributing to more severe bacterial and viral respiratory infections in obesity and diabetes. Her research provides critical insights into the role of cholesterol and its derivatives in regulation of inflammation in the lung and how this knowledge can be exploided for novel therapeutic approaches to treat respiratory infections.